{"filing":{"accession_number":"0001104659-26-094433","cik":"0001006281","ticker":"PLX","company_name":"Protalix BioTherapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"plx-20260812x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812x8k.htm"},"events":[{"id":27008,"run_id":24575,"accession_number":"0001104659-26-094433","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Protalix's financial results for the second quarter and first half of 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $19.8 million, year-to-date revenues of $53.6 million, and year-to-date net income of $22.1 million, along with full-year 2026 revenue guidance of $78.0–$83.0 million. The disclosure includes detailed financial highlights, operational updates on product commercialization (Elfabrio®) and clinical programs (PRX-115), and is accompanied by a conference call. This is a material event affecting investor assessment of the company's financial performance and operational progress.","company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28339,"accession_number":"0001104659-26-094433","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Protalix's financial results for the second quarter and first half of 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $19.8 million, year-to-date revenues of $53.6 million, and year-to-date net income of $22.1 million, along with full-year 2026 revenue guidance of $78.0–$83.0 million. The disclosure includes detailed financial highlights, operational updates on product commercialization (Elfabrio®) and clinical programs (PRX-115), and is accompanied by a conference call. This is a material event affecting investor assessment of the company's financial performance and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:00:52.891855+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28339,"accession_number":"0001104659-26-094433","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Protalix's financial results for the second quarter and first half of 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $19.8 million, year-to-date revenues of $53.6 million, and year-to-date net income of $22.1 million, along with full-year 2026 revenue guidance of $78.0–$83.0 million. The disclosure includes detailed financial highlights, operational updates on product commercialization (Elfabrio®) and clinical programs (PRX-115), and is accompanied by a conference call. This is a material event affecting investor assessment of the company's financial performance and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:00:52.891855+00:00","company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","filing_date":"2026-08-12"}]}